ArticleYonsei medical journal2018

Clinical Outcomes of Low-Dose Methotrexate Therapy as a Second-Line Drug for Intravenous Immunoglobulin-Resistant Kawasaki Disease.

Hyejin Jang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.